Clinical medicine profile
chlorpheniramine mal.2mg, ephedrine Hcl 8mg, codeine phosp. 8mg, NH4Cl 80mg/5mL
Opioid analgesic
- Route
- ORAL / IV / IM / SC / TD / RECTAL
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Acute respiratory depression, severe asthma/COPD without monitoring, paralytic ileus, acute alcoholism, raised intracranial pressure in unstable settings, MAOI interactions for some agents.
Precautions
- [From component Chlorpheniramine] Warnings Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Prefer fentanyl/methadone expert use over morphine in advanced CKD; reduce doses.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Reduce dose/frequency; avoid long-acting in decompensated disease.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Opioid analgesic).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Cough suppressant (anti-tussive)
Adverse effects
- [From component Chlorpheniramine] Drowsiness
- psychomotor impairment
- anti-muscarinic effects [e.g. urinary retention
- dry mouth
- GI disturbances
- blurred vision]
- allergic reactions
- epileptic form seizure in patients with cerebral cortex focal lesion
- muscle weakness
- tachycardia
- tight chest
- paradoxical CNS stimulation - mostly in children.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Chlorpheniramine.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Chlorpheniramine): It acts by competing with histamine for H1-receptor sites on effector cells. Its anticholinergic actions give a drying effect on the nasal mucosa.
Minutes (IV) to hour (oral)
Hours (agent-dependent)
ORAL / IV / IM / SC / TD / RECTAL
(CYP2D6 critical for codeine/tramadol activation — ultrarapid metabolisers risk toxicity; poor metabolisers lack efficacy). Renal
of active metabolites (morphine-6-glucuronide accumulates in CKD).
Pregnancy, lactation & diet
Use only if necessary; neonatal withdrawal with chronic maternal use. Prefer specialist obstetric advice.
Codeine generally avoided (CYP2D6). Short-term morphine sometimes used with monitoring — check guidance.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| BRONKOF SYRUP * | DAIMA BIASHARA / Wholesale Import | 100ML | KES 120.40Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.